Biopharma | January 11, 2026
InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
Subscribe To Our Newsletter & Stay Updated
